Ezetimibe and the risk of new-onset type 2 diabetes: a systematic review and meta-analysis
Background Statins reduce cardiovascular risk but may increase new-onset type 2 diabetes mellitus (NO-T2DM). Ezetimibe, a cholesterol absorption inhibitor, is often added to statins to improve lipid control, yet its impact on NO-T2DM remains uncertain.Objective This systematic review evaluated moder...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Taylor & Francis Group
2025-12-01
|
| Cyfres: | Annals of Medicine |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.tandfonline.com/doi/10.1080/07853890.2025.2594355 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
